VRTX

VERTEX PHARMACEUTICALS INC

Data as of 2026 Q2 (06-30) · 13F snapshot

Summary

VERTEX PHARMACEUTICALS INC (VRTX) is held as common stock by 7 tracked hedge-fund managers, with a combined reported value of ~$676.30M; the largest are Ken Griffin, Izzy Englander, Renaissance Technologies. 4 tracked managers also disclosed PUT or CALL positions, reported separately below. This quarter: 2 new, 2 added, 3 trimmed. 20 public STOCK Act / OGE trade disclosures are on record. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.

Attention · MediumThis quarter · Mixed

Common-stock holders74 also report options

Congress trades20

Price$527.67vs quarter-end+6.23%

Sectors2

This quarter's moves

New2

Added2

Trimmed / sold3

Top holder

Ken Griffin

Common-stock positions

PUT and CALL disclosures are excluded from these holder counts and values.

Investor	Period	Value	Shares	% of portfolio	Action

PUT / CALL disclosures

Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.

Ken GriffinCALL—

Value $121.50M— of portfolio244,6002026 Q2

Ken GriffinPUT—

Value $66.86M— of portfolio134,6002026 Q2

Izzy EnglanderPUT—

Value $24.34M— of portfolio49,0002026 Q2

Izzy EnglanderCALL—

Value $23.05M— of portfolio46,4002026 Q2

Steven CohenCALL—

Value $7.15M— of portfolio14,4002026 Q2

Paul Tudor JonesCALL—

Value $2.68M— of portfolio5,4002026 Q2

Steven CohenPUT—

Value $794.8K— of portfolio1,6002026 Q2

Paul Tudor JonesPUT—

Value $596.1K— of portfolio1,2002026 Q2

Investor	Period	Value	Shares	% of portfolio	Action
Ken GriffinCALL	2026 Q2	$121.50M	244,600	—	—
Ken GriffinPUT	2026 Q2	$66.86M	134,600	—	—
Izzy EnglanderPUT	2026 Q2	$24.34M	49,000	—	—
Izzy EnglanderCALL	2026 Q2	$23.05M	46,400	—	—
Steven CohenCALL	2026 Q2	$7.15M	14,400	—	—
Paul Tudor JonesCALL	2026 Q2	$2.68M	5,400	—	—
Steven CohenPUT	2026 Q2	$794.8K	1,600	—	—
Paul Tudor JonesPUT	2026 Q2	$596.1K	1,200	—	—

Insider Trading

Officers · directors · Form 4

Open-market purchases and sales (P/S)13

Duncan Mckechnie
EVP, Chief Commercial Officer
Sell$799.8K
1,541 @ $519.00Traded 2026-07-02Filed 2026-07-07
Ourania Tatsis
EVP, Chief Reg. & Quality Off.
Sell$787.5K
1,500 @ $524.99Traded 2026-07-02Filed 2026-07-07
Joy Liu
EVP and Chief Legal Officer
Sell$416.2K
828 @ $502.71Traded 2026-07-01Filed 2026-07-06
Carmen Bozic
EVP and CMO
Sell$287.6K
596 @ $482.50Traded 2026-06-26Filed 2026-06-30
Carmen Bozic
EVP and CMO
Sell$471.4K
1,020 @ $462.17Traded 2026-06-18Filed 2026-06-23
Carmen Bozic
EVP and CMO
Sell$1.83M
4,062 @ $450.00Traded 2026-06-15Filed 2026-06-17
Carmen Bozic
EVP and CMO
Sell$785.3K
1,745 @ $450.00Traded 2026-06-05Filed 2026-06-09
Joy Liu
EVP and Chief Legal Officer
Sell$364.2K
828 @ $439.91Traded 2026-06-01Filed 2026-06-03
Carmen Bozic
EVP and CMO
Sell$888.3K
1,974 @ $450.00Traded 2026-05-29Filed 2026-06-02
Mark E. Bunnage
EVP, Chief Scientific Officer
Sell$15.0K
33 @ $453.45Traded 2026-05-15Filed 2026-05-19
Carmen Bozic
EVP and CMO
Sell$614.0K
1,354 @ $453.45Traded 2026-05-15Filed 2026-05-19
Carmen Bozic
EVP and CMO
Sell$3.14M
6,988 @ $450.00Traded 2026-05-12Filed 2026-05-14
Joy Liu
EVP and Chief Legal Officer
Sell$469.2K
1,104 @ $425.02Traded 2026-05-01Filed 2026-05-05

Insider transactions are public SEC Form 4 disclosures (company officers, directors, 10% owners), for research only — not investment advice.

Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.